Symbols / TSHA Stock $5.96 -5.40% Taysha Gene Therapies, Inc.

Healthcare • Biotechnology • United States • NMS
TSHA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Sean P. Nolan
Exch · Country NMS · United States
Market Cap 1.71B
Enterprise Value 1.50B
Income -129.88M
Sales 7.47M
FCF (ttm) -73.45M
Book/sh 0.87
Cash/sh 0.96
Employees 99
Insider 10d —
IPO Sep 24, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.47
PEG —
P/S 229.24
P/B 6.88
P/C —
EV/EBITDA -11.45
EV/Sales 201.40
Quick Ratio 13.76
Current Ratio 14.04
Debt/Eq 32.34
LT Debt/Eq —
EPS (ttm) -0.38
EPS next Y -0.44
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-05-06
ROA -37.77%
ROE -97.28%
ROIC —
Gross Margin 100.00%
Oper. Margin -17.74%
Profit Margin 0.00%
Shs Outstand 287.36M
Shs Float 198.57M
Insider Own 10.62%
Instit Own 95.41%
Short Float 14.19%
Short Ratio 14.10
Short Interest 40.05M
52W High 7.30
vs 52W High -18.36%
52W Low 2.25
vs 52W Low 164.89%
Beta 1.23
Impl. Vol. 41.03%
Rel Volume 1.17
Avg Volume 2.77M
Volume 3.24M
Target (mean) $12.23
Tgt Median $12.00
Tgt Low $8.00
Tgt High $19.00
# Analysts 13
Recom Strong_buy
Prev Close $6.30
Price $5.96
Change -5.40%
About

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.23
Mean price target
2. Current target
$5.96
Latest analyst target
3. DCF / Fair value
$-4.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.96
Low
$8.00
High
$19.00
Mean
$12.23

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Canaccord Genuity Buy → Buy $17
2026-03-19 main Chardan Capital Buy → Buy $12
2026-03-19 main Needham Buy → Buy $12
2026-03-03 reit Needham Buy → Buy $10
2026-01-06 main Chardan Capital Buy → Buy $12
2026-01-05 main Wells Fargo Overweight → Overweight $11
2025-11-05 main Citizens Market Outperform → Market Outperform $8
2025-11-05 main Chardan Capital Buy → Buy $12
2025-10-21 init Raymond James — → Strong Buy $13
2025-10-17 main Chardan Capital Buy → Buy $12
2025-10-17 reit Needham Buy → Buy $10
2025-10-02 main Baird Outperform → Outperform $12
2025-10-02 main Needham Buy → Buy $10
2025-08-13 main Wells Fargo Overweight → Overweight $8
2025-08-13 main Canaccord Genuity Buy → Buy $14
2025-08-12 main Chardan Capital Buy → Buy $10
2025-07-11 init B of A Securities — → Buy $8
2025-07-01 reit Needham Buy → Buy $8
2025-06-10 reit Needham Buy → Buy $8
2025-06-03 main Canaccord Genuity Buy → Buy $11
News
RSS: Latest TSHA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-10 NAGENDRAN SUKUMAR President — 19,021 $1.71 $32,526
2026-04-10 NAGENDRAN SUKUMAR President — 200,000 $4.46 $892,000
2026-02-04 ALAM KAMRAN Chief Financial Officer — 1,655 $4.52 $7,481
2026-01-26 NOLAN SEAN PATRICK Chief Executive Officer — 178,101 $4.61 $840,196
2026-01-26 NAGENDRAN SUKUMAR Officer and Director — 116,050 $4.61 $547,469
2026-01-26 ALAM KAMRAN Chief Financial Officer — 102,817 $4.61 $485,042
2026-01-12 NAGENDRAN SUKUMAR Officer and Director — 200,000 $0.70 $229,440
2026-01-12 NAGENDRAN SUKUMAR Officer and Director — 200,000 $4.71 $942,000
2026-01-12 NOLAN SEAN PATRICK Chief Executive Officer — 1,008,000 $0.00 $0
2026-01-12 NAGENDRAN SUKUMAR Officer and Director — 427,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
9.77
+17.28%
8.33
-46.07%
15.45
+517.55%
2.50
Operating Revenue
9.77
+17.28%
8.33
-46.07%
15.45
+517.55%
2.50
Operating Expense
120.27
+26.66%
94.95
+9.36%
86.83
-32.45%
128.53
Research And Development
86.40
+30.91%
66.00
+16.24%
56.78
-37.72%
91.17
Selling General And Administration
33.87
+16.98%
28.95
-3.64%
30.05
-19.57%
37.36
General And Administrative Expense
33.87
+16.98%
28.95
-3.64%
30.05
-19.57%
37.36
Other Gand A
33.87
+16.98%
28.95
-3.64%
30.05
-19.57%
37.36
Total Expenses
120.27
+26.66%
94.95
+9.36%
86.83
-32.45%
128.53
Operating Income
-110.50
-27.56%
-86.62
-21.36%
-71.37
+43.37%
-126.03
Total Operating Income As Reported
-110.50
-20.82%
-91.46
-26.26%
-72.44
+55.41%
-162.45
EBITDA
-107.79
-22.55%
-87.95
+16.39%
-105.20
+34.68%
-161.04
Normalized EBITDA
-106.59
-28.22%
-83.13
-22.22%
-68.02
+45.42%
-124.62
Reconciled Depreciation
1.15
-8.03%
1.25
-9.19%
1.37
+16.98%
1.17
EBIT
-108.93
-22.13%
-89.20
+16.30%
-106.57
+34.30%
-162.22
Total Unusual Items
-1.20
+75.13%
-4.82
+87.03%
-37.18
-2.09%
-36.42
Total Unusual Items Excluding Goodwill
-1.20
+75.13%
-4.82
+87.03%
-37.18
-2.09%
-36.42
Special Income Charges
0.00
+100.00%
-4.84
-96.43%
-2.46
+93.24%
-36.42
Other Special Charges
—
—
1.40
—
Impairment Of Capital Assets
0.00
-100.00%
4.84
+354.27%
1.06
-97.08%
36.42
Net Income
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Pretax Income
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Net Non Operating Interest Income Expense
9.16
+33.97%
6.84
+579.52%
-1.43
+59.82%
-3.55
Interest Expense Non Operating
0.06
-38.24%
0.10
-97.96%
5.00
+31.60%
3.80
Net Interest Income
9.16
+33.97%
6.84
+579.52%
-1.43
+59.82%
-3.55
Interest Expense
0.06
-38.24%
0.10
-97.96%
5.00
+31.60%
3.80
Interest Income Non Operating
9.22
+32.91%
6.94
+94.29%
3.57
+1334.54%
0.25
Interest Income
9.22
+32.91%
6.94
+94.29%
3.57
+1334.54%
0.25
Other Income Expense
-7.66
+19.52%
-9.52
+75.46%
-38.77
-6.39%
-36.44
Other Non Operating Income Expenses
-6.46
-37.63%
-4.69
-196.09%
-1.58
-8705.56%
-0.02
Gain On Sale Of Security
-1.20
-7593.75%
0.02
+100.05%
-34.72
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Net Income From Continuing Operation Net Minority Interest
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Net Income From Continuing And Discontinued Operation
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Net Income Continuous Operations
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Normalized Income
-107.80
-27.61%
-84.48
-13.57%
-74.39
+42.60%
-129.59
Net Income Common Stockholders
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Diluted EPS
—
-0.36
+62.50%
-0.96
+74.60%
-3.78
Basic EPS
—
-0.36
+62.50%
-0.96
+74.60%
-3.78
Basic Average Shares
—
250.13
+115.41%
116.12
+164.20%
43.95
Diluted Average Shares
—
250.13
+115.41%
116.12
+164.20%
43.95
Diluted NI Availto Com Stockholders
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Line Item Trend 2023-12-31
Total Assets
172.73
Current Assets
149.87
Cash Cash Equivalents And Short Term Investments
143.94
Cash And Cash Equivalents
143.94
Cash Equivalents
142.43
Cash Financial
1.51
Prepaid Assets
2.51
Current Deferred Assets
0.68
Restricted Cash
0.45
Assets Held For Sale Current
2.00
Other Current Assets
0.29
Total Non Current Assets
22.86
Net PPE
20.41
Gross PPE
23.39
Accumulated Depreciation
-2.98
Properties
0.00
Machinery Furniture Equipment
2.00
Construction In Progress
6.82
Other Properties
12.45
Leases
2.12
Non Current Deferred Assets
—
Other Non Current Assets
2.46
Total Liabilities Net Minority Interest
97.79
Current Liabilities
36.76
Payables And Accrued Expenses
12.01
Payables
6.37
Accounts Payable
6.37
Current Accrued Expenses
5.65
Pensionand Other Post Retirement Benefit Plans Current
3.81
Current Debt And Capital Lease Obligation
1.65
Current Capital Lease Obligation
1.65
Current Deferred Liabilities
18.11
Current Deferred Revenue
18.11
Other Current Liabilities
1.18
Total Non Current Liabilities Net Minority Interest
61.04
Long Term Debt And Capital Lease Obligation
59.46
Long Term Debt
40.51
Long Term Capital Lease Obligation
18.95
Other Non Current Liabilities
1.58
Stockholders Equity
74.94
Common Stock Equity
74.94
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
186.96
Ordinary Shares Number
186.96
Treasury Shares Number
0.00
Additional Paid In Capital
587.94
Retained Earnings
-513.01
Gains Losses Not Affecting Retained Earnings
0.00
Other Equity Adjustments
—
Total Equity Gross Minority Interest
74.94
Total Capitalization
115.44
Working Capital
113.11
Invested Capital
115.44
Total Debt
61.11
Capital Lease Obligations
20.60
Net Tangible Assets
74.94
Tangible Book Value
74.94
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-93.09
-14.61%
-81.22
-11.24%
-73.02
+17.39%
-88.39
Cash Flow From Continuing Operating Activities
-93.09
-14.61%
-81.22
-11.24%
-73.02
+17.39%
-88.39
Net Income From Continuing Operations
-109.00
-22.06%
-89.30
+19.96%
-111.57
+32.80%
-166.01
Depreciation Amortization Depletion
1.15
-8.03%
1.25
-9.19%
1.37
+16.98%
1.17
Depreciation
1.15
-8.03%
1.25
-9.19%
1.37
+16.98%
1.17
Depreciation And Amortization
1.15
-8.03%
1.25
-9.19%
1.37
+16.98%
1.17
Other Non Cash Items
5.63
+311.24%
1.37
-85.22%
9.27
+167.01%
3.47
Stock Based Compensation
13.30
+1.49%
13.10
+65.76%
7.91
-56.19%
18.04
Asset Impairment Charge
0.00
-100.00%
4.84
+354.27%
1.06
-97.08%
36.42
Operating Gains Losses
1.20
+7593.75%
-0.02
-100.04%
36.95
—
Gain Loss On Investment Securities
1.20
+7593.75%
-0.02
-100.04%
35.59
—
Change In Working Capital
-5.37
+56.92%
-12.47
+30.79%
-18.01
-197.27%
18.52
Change In Prepaid Assets
-1.73
-937.68%
0.21
-96.56%
6.01
+187.88%
2.09
Change In Payables And Accrued Expense
6.14
+241.35%
-4.34
+49.36%
-8.57
+49.95%
-17.13
Change In Accrued Expense
6.29
+542.58%
-1.42
+77.36%
-6.28
+32.67%
-9.32
Change In Payable
-0.15
+94.76%
-2.92
-27.23%
-2.29
+70.59%
-7.80
Change In Account Payable
-0.15
+94.76%
-2.92
-27.23%
-2.29
+70.59%
-7.80
Change In Other Working Capital
-9.77
-17.28%
-8.33
+46.07%
-15.45
-146.04%
33.56
Investing Cash Flow
-0.60
-66.39%
-0.36
+95.06%
-7.35
+70.51%
-24.93
Cash Flow From Continuing Investing Activities
-0.60
-66.39%
-0.36
+95.06%
-7.35
+70.51%
-24.93
Net PPE Purchase And Sale
-0.74
-97.33%
-0.37
+90.33%
-3.87
+81.24%
-20.62
Purchase Of PPE
-0.74
-97.33%
-0.37
+90.33%
-3.87
+81.24%
-20.62
Capital Expenditure
-0.74
-97.33%
-0.37
+94.92%
-7.37
+70.37%
-24.87
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-3.50
+17.65%
-4.25
Purchase Of Intangibles
—
0.00
+100.00%
-3.50
+17.65%
-4.25
Net Other Investing Changes
0.13
+1118.18%
0.01
-35.29%
0.02
+127.87%
-0.06
Financing Cash Flow
274.59
+258.08%
76.68
-43.78%
136.39
+161.81%
52.10
Cash Flow From Continuing Financing Activities
274.59
+258.08%
76.68
-43.78%
136.39
+161.81%
52.10
Net Issuance Payments Of Debt
9.24
0.00
+100.00%
-3.45
0.00
Issuance Of Debt
49.85
0.00
-100.00%
39.55
0.00
Repayment Of Debt
-40.61
0.00
+100.00%
-43.00
0.00
Long Term Debt Issuance
49.85
0.00
-100.00%
39.55
0.00
Long Term Debt Payments
-40.61
0.00
+100.00%
-43.00
0.00
Net Long Term Debt Issuance
9.24
0.00
+100.00%
-3.45
0.00
Net Common Stock Issuance
264.31
+244.24%
76.78
-45.46%
140.79
+164.42%
53.24
Proceeds From Stock Option Exercised
1.38
+1449.44%
0.09
+30.88%
0.07
-73.12%
0.25
Net Other Financing Charges
-0.34
-82.16%
-0.18
+81.77%
-1.01
+27.50%
-1.40
Changes In Cash
180.90
+3788.72%
-4.90
-108.75%
56.02
+191.51%
-61.22
Beginning Cash Position
141.64
-3.35%
146.54
+61.89%
90.52
-40.35%
151.74
End Cash Position
322.53
+127.72%
141.64
-3.35%
146.54
+61.89%
90.52
Free Cash Flow
-93.83
-14.99%
-81.60
-1.51%
-80.39
+29.02%
-113.26
Interest Paid Supplemental Data
5.40
+2.22%
5.28
+6.66%
4.95
+78.45%
2.77
Common Stock Issuance
264.31
+244.24%
76.78
-45.46%
140.79
+164.42%
53.24
Issuance Of Capital Stock
264.31
+244.24%
76.78
-45.46%
140.79
+164.42%
53.24
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category